Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Apr;19(2):92-6.
doi: 10.1016/j.breast.2009.12.001. Epub 2010 Jan 15.

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

Stephanie L Hines  1 , Jeff A Sloan, Pamela J Atherton, Edith A Perez, Shaker R Dakhil, David B Johnson, Pavan S Reddy, Robert J Dalton, Bassam I Mattar, Charles L Loprinzi
Affiliations
Clinical Trial

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

Stephanie L Hines et al. Breast. 2010 Apr.

Abstract

Background: Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole.

Patients and methods: Postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer and a bone mineral density (BMD) T-score <-2.0 were given letrozole 2.5mg/vitamin D 400 international units daily, calcium 500mg twice daily, and 4mg zoledronic acid every 6 months. The BMD was assessed at baseline and 1 year. The primary endpoint was the mean change in lumbar spine (LS) BMD at 1 year.

Results: Forty-six patients completed 1 year of treatment. LS BMD increased by 2.66% (p=0.01), femoral neck (FN) by 4.81% (p=0.01), and any measured endpoint by 4.55% (p=0.0052).

Conclusions: Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Hines, Dr. Perez, and Dr. Loprinzi report some research funding from Novartis. Otherwise, no conflicts of interest are present.

Figures

Figure 1
Figure 1
Patient Flow
See this image and copyright information in PMC

References

    1. Perez EA, Weilbaecher K. Aromatase Inhibitors and Bone Loss. Oncology. 2006;20(9):1029–1039. - PMC - PubMed
    2. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone replacement therapy. NEJM. 1991;325(17):1189–95. - PubMed
    1. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. NEJM. 1987;316(4):173–7. - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. - PubMed
    1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701–12. - PubMed
    1. Powles T, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of Tamoxifen on Bone Mineral Density Measured by Dual-Energy X-Ray Absorptiometry in Healthy Premenopausal and Postmenopausal Women. J Clin Oncol. 1996;14(1):78–84. - PubMed

Publication types

MeSH terms